VistaGen Therapeutics (VTGN) Expected to Announce Quarterly Earnings on Thursday

Key Points

• VistaGen Therapeutics is set to release its Q1 2026 earnings on August 7th, expecting to report earnings of ($0.46) per share and revenue of $0.22 million.
• Shares of VistaGen Therapeutics (VTGN) increased by 1.7%, trading at $2.92, with a market capitalization of $85.15 million.
• Institutional investor Bank of America Corp DE significantly raised its position in VistaGen Therapeutics by 1,068.0%, owning approximately 0.08% of the company after acquiring additional shares.

VistaGen Therapeutics (NASDAQ:VTGN - Get Free Report) will likely be issuing its Q1 2026 quarterly earnings data after the market closes on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.46) per share and revenue of $0.22 million for the quarter.

VistaGen Therapeutics (NASDAQ:VTGN - Get Free Report) last issued its quarterly earnings data on Tuesday, June 17th. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.09. The company had revenue of ($0.01) million for the quarter, compared to analyst estimates of $0.18 million. VistaGen Therapeutics had a negative net margin of 6,777.08% and a negative return on equity of 58.88%. During the same period in the prior year, the firm earned ($0.25) earnings per share. On average, analysts expect VistaGen Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

VistaGen Therapeutics Stock Down 0.3%

Shares of VTGN traded down $0.01 during trading hours on Tuesday, hitting $2.90. The company had a trading volume of 64,558 shares, compared to its average volume of 211,519. The firm has a market cap of $86.59 million, a price-to-earnings ratio of -1.72 and a beta of 0.40. The business has a fifty day moving average of $2.41 and a 200-day moving average of $2.50. VistaGen Therapeutics has a 12 month low of $1.90 and a 12 month high of $3.79.

Wall Street Analysts Forecast Growth

Separately, William Blair restated an "outperform" rating on shares of VistaGen Therapeutics in a research note on Wednesday, June 18th.

Hedge Funds Weigh In On VistaGen Therapeutics

A hedge fund recently bought a new stake in VistaGen Therapeutics stock. Cubist Systematic Strategies LLC acquired a new position in shares of VistaGen Therapeutics, Inc. (NASDAQ:VTGN - Free Report) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 10,088 shares of the company's stock, valued at approximately $25,000. Institutional investors own 78.39% of the company's stock.

About VistaGen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.